Asia-Pacific Herpes Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Asia-Pacific Herpes Market

Asia-Pacific herpes market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyzes that the Asia-Pacific herpes market is growing with a CAGR of 5.6% in the forecast period of 2021 to 2028 and is expected to reach USD 269.74 million by 2028 from USD 181.72 million in 2020. Rising prevalence of herpes infections and increasing geriatric population are major drivers, which are expected to boost the growth of the market in the forecast period.

A growing number of people are affected with by the herpes simplex virus, which demands highly effective and advanced anti-herpetic treatment to minimize the risk during the treatment. The healthcare systems need highly advanced drugs for numerous different types of herpes during the treatment of patients. Therefore, major market players are highly focusing on product launches and product approvals. Additionally, governments and regulatory bodies are supporting market players by virtue of product approvals.

Rising prevalence of herpes diseases and increase in health expenditure across regions have accelerated the need for anti-herpetic drugs in healthcare facilities, which is driving the growth of the herpes market. In addition, surging volume of geriatric people is further propelling the market growth. However, high cost of anti-herpetic medicines and product recalls are anticipated to hinder market growth in the projected period. On the other hand, strategic initiatives by market players and soaring number of anti-herpetic drugs manufacturers act as an opportunity for this market and is expected to impel the market growth. However, disruption in supply chain of herpes drugs and injections during covid-19 and lack of workforce in pharma industries are key challenges for this market.

The Asia-Pacific herpes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.   

The Asia-Pacific Herpes Market Scope and Market Size

The Asia-Pacific herpes market is segmented on the basis of virus type, product, drug type, age, route of administration, distribution channel, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of virus type, the Asia-Pacific herpes market is segmented into herpes simplex and herpes zoster. In 2021, herpes simplex segment is expected to dominate the market due to rise in prevalence of herpes infections owing to unprotected sex with an infected partner.  
• On the basis of product, the Asia-Pacific herpes market is segmented into acyclovir, docosanol, valacyclovir, famciclovir, and others. In 2021, acyclovir segment is expected to dominate the market due to increasing launch of new drugs by pharmaceutical manufacturers.
• On the basis of drug type, the Asia-Pacific herpes market is segmented into prescription drug and over-the counter drug. In 2021, prescription drug segment is expected to dominate the market owing to growing pharmaceutical market in the region.
• On the basis of age, the Asia-Pacific herpes market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the market owing to rising geriatric population In China, Japan, and India.
• On the basis of route of administration, the Asia-Pacific herpes market is segmented into topical, oral, and parenteral. In 2021, topical segment is expected to dominate the market owing to greater patient compliance and better aid in quick healing. 
• On the basis of distribution channel, the Asia-Pacific herpes market is segmented into hospitals pharmacies, retail pharmacies, drug stores, online pharmacies, and others. In 2021, hospital pharmacies segment is expected to dominate the market owing to wider availability of anti-herpetic drugs.
• On the basis of end-users, the Asia-Pacific herpes market is segmented into hospital, speciality clinics, and others. In 2021, hospitals segment is expected to dominate the market due to rising new product launches associated with this segment.

Asia-Pacific Herpes Market Country Level Analysis

The Asia-Pacific herpes market is analyzed and market size information is provided based on virus type, product, drug type, age, route of administration, distribution channel, and end users. 

Countries covered in the Asia-Pacific herpes market report are China, India, Japan, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia Philippines, and Rest of Asia-Pacific. The Asia-Pacific region is expected to grow with the most promising growth rate in the forecast period of 2021 to 2028 because of rising prevalence geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Rising healthcare expenditure and high prevalence of herpes infections in the Asia-Pacific creating new opportunities for players in the Asia-Pacific herpes market

Herpes simplex segment is dominating in China, which is leading in the Asia-Pacific region owing to growing geriatric population in the country.

Asia-Pacific herpes market also provides you with detailed market analysis for every country growth in particular industry with the Asia-Pacific herpes market sales, impact of advancement in the Asia-Pacific herpes market and changes in regulatory scenarios with their support for the Asia-Pacific herpes market. The data is available for historic period 2010 to 2018. 

Competitive Landscape and Asia-Pacific herpes market Share Analysis

Asia-Pacific herpes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to Asia-Pacific herpes market.

Major players covered in the report are Abbott, Apotex, Inc., Avet Pharmaceuticals, Inc., Bausch Health Companies, Inc. Cipla, Inc., Dr. Reddy’s Laboratories Ltd., EPI Health, Fresenius Kabi AG, GlaxoSmithKline plc., Glenmark Pharmaceutical Inc., USA, Maruho Co.,Ltd.,  Mylan N.V.,  Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., RECORDATI S.p.A., Aurobindo Pharma, Amneal Pharmaceuticals LLC, Slavia Pharm S.R.L., and Blistex, Inc.,  among others domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies worldwide, which are further accelerating the growth of the Asia-Pacific herpes market.

For instance,

• In November 2019, In November, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer, the new company formed would be named Viatris. The merger of both the companies to develop a combined firm has expanded its product portfolio leading to increased demand for its product in the market.
• In September 2018, Avet Pharmaceuticals Inc. announced the immediate availability of Acyclovir 200mg Capsules. This launch enhanced Avet’s broad portfolio of generic oral solid products. This new drug launched by the company has increased its sales and demand in the market, leading to increased revenue in the future. This helped the company increase its product line.

SKU-64368